Core Viewpoint - WuXi AppTec's CAR-T product, Benodida, along with four other CAR-T therapies, has successfully passed expert review for inclusion in the 2025 National Basic Medical Insurance Directory and Commercial Insurance Innovative Drug Directory, signaling a positive regulatory shift towards improving access to cutting-edge therapies [1] Group 1: Stock Performance - WuXi AppTec-B (02126) saw a nearly 7% intraday increase, currently up 6.1% at HKD 4.35, with a trading volume of HKD 7.2867 million [1] Group 2: Regulatory Developments - The National Healthcare Security Administration announced the completion of expert review for the 2025 National Basic Medical Insurance Directory and Commercial Insurance Innovative Drug Directory adjustments [1] - The inclusion of CAR-T therapies in the review indicates a commitment from regulators to enhance the accessibility of advanced treatments [1] Group 3: Market Context - CAR-T therapies have not been included in the basic medical insurance directory due to their high cost, often exceeding one million yuan per injection [1] - Currently, CAR-T therapy payment structures are diversified, relying primarily on commercial health insurance, supplemented by special disease insurance, financial installment plans, and various assistance programs [1] Group 4: Company Response - WuXi AppTec has stated that its CAR-T products will actively participate in the application process for the 2025 medical insurance and commercial insurance innovative drug directories [1] - Over 70 commercial health insurance products have already included WuXi AppTec's Benodida [1]

Core Viewpoint - China Biotechnology Services (08037) announced that its indirect non-wholly owned subsidiary, Shanghai Longyao Biotechnology Co., Ltd., will present the Phase I clinical trial results of LY007 cell injection at two major international conferences in 2025, highlighting its potential to fill the treatment gap in CD20 CAR-T therapy [1] Group 1: Efficacy and Safety - LY007 features a unique OX40 co-stimulation signal design that significantly enhances T cell expansion and anti-tumor activity. Phase I clinical trial data shows that 92% of 12 patients with relapsed/refractory CD20-positive B-cell non-Hodgkin lymphoma experienced tumor reduction or disappearance, with a best complete response rate (BCRR) of 75%. One patient who failed CD19 CAR-T treatment achieved complete remission without severe cytokine release syndrome or neurotoxicity [2] Group 2: Differentiated Indication Strategy - LY007 offers a new treatment option for patients who failed CD19 CAR-T therapy or are CD19-negative relapsed. The CAR-T cells peaked at 46% to 80% of CD3+ T cells in patients. Shanghai Longyao plans to further promote international multicenter clinical research for LY007 at the International Conference on Malignant Lymphoma and the European Hematology Association meeting, exploring collaborations with European and American institutions. The company has laid out 14 global patents to support product commercialization and expansion into solid tumor indications. Over the past year, the Phase I clinical research results of LY007 have been presented at major global oncology and hematology conferences, indicating recognition and attention in the global academic field [3]